NSABP B-37 - A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-regional Relapse of Breast Cancer.  Arm A: patients will receive current “standard” therapy. Arm B: patients will receive “standard” therapy plus chemotherapy.   

NSABP B-40 - A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens.

NSABP B-42 - Registration Program to Provide Up to 3 years of Letrozole to Postmenopausal Women with Hormone Receptor Positive Breast Cancer Who Have Received at Least 2 years of Initial Adjuvant Hormonal Therapy.

NSABP B-42 - Clinical trial to determine the efficacy of 5 years of Letrozole compared to placebo in pts. Completing 5 years of hormonal therapy consisting of an aromatase inhibitor or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer.

CALGB 40101 - Phase III cyclophosphamide and Doxorubicin (CA 4 vs. 6 cycles) versus Paclitaxel (4 vs. 6 cycles) asadjuvant therapy for women with node-negative breast cancer. 

NSABP B-36 - A clinical Trial of Adjuvant Therapy Comparing 6 cycles of 5-FU, Epirubicin and Cyclophosphamide (FEC) to 4 cycles of Adriamycin and Cyclophosphamide (AC) in patients with node negative breast cancer (PSOC).

CTSU MA.27 - A Randomized Phase III trial of Exemestane versus Anastrozole in postmenopausal women with receptor positive primary breast cancer.

SWOG S0221 - A Phase III Trial of Continuous Schedule AC + G Vs Q2Week AC, Followed by Taxol Given Either Q2Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node Positive or High Risk Node-Negative Breast Cancer. (Stage I, II, or III).

AVF3991n
ARIES Registry - An observational study of Avastin in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer.

CALGB 80405 - Phase II trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (FOLFOX) with Bevacizumab (Avastin) or Cetuximab (Erbitux) or with the combination of Avastin and Erbitux for patients with untreated metastatic adenocarcinoma of the colon or rectum.  

Adventrx - A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (%-FU) plus Bevacizumab vs. Leucovorin and 5-FU plus Bevacizumab as Initial treatment for Metastatic Colorectal Carcinoma.

NO147
(Adjuvant) - A randomized Phase III trial of Oxaliplatin plus 5-FU/Leucovorin (CF) with or without Cetuximab (Erbitux) after curative resection for patients with Stage III colon cancer.

NSABP R-04 - A clinical trial comparing preoperative RT and Capecitabine (Xeloda) vs. preoperative RT and continuous intravenous infusion of 5-FU in the treatment of patients with operable carcinoma of the rectum.

CALGB 90401 - Phase III Randomized, double-blind placebo controlled trial comparing Docetaxel (Taxotere) and Prednisone with or without Bevacizumab (Avastin) in men with hormone refractory prostate cancer.

OVARIAN / PERITONEAL

GOG 170F - A Phase II Evaluation of BAY-9006 in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma.  (PSOC)

GOG 212 - A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or XyotaxTM (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who                 Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

GOG 218 - A Phase III trial of carboplatin and paclitaxel plus placebo Vs. carboplatin and paclitaxel plus concurrent Bevacizumab followed by placebo, Vs. carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosed, previously untreated, suboptimal advanced stage epithelial ovarian and primary peritoneal cancer.

ENDOMETRIAL

GOG 0209 - A Randomized Phase III trial of Doxorubicin/Cisplatin/Paclitaxel/G-CSF Vs. Carboplatin/Paclitaxel in patients with Stage III & IV or recurrent endometrial cancer.

CERVIX / VULVA

GOG 204 - A Randomized Phase III trial of Paclitzel plusCisplatin Vs. Vinorelbine plus Cisplatin Vs. Gemcitabine plus Cisplatin Vs. Topotecan plus Cisplatin in Stage IVB recurrent or persistent carcinoma of the cervix.

GOG 219 - A Phase III Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis.

GOG 227C - A Phase II Evaluation of Bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix.

SWOG E5597 - A Phase III chemoprevention trial of Selenium supplementation in persons with resected Stage I non-small cell lung cancer.

POI-01-003-050 - A Randomized multicenter study of combination Gemcitabine therapy followed by subsequent single agent Gemcitabine maintenance therapy Vs. best supportive care in advanced Stage IIIb or IV NSCLC.

AVF3991n
ARIES Registry - An observational study of Avastin in combination of chemotherapy for treatment of locally advanced or metastatic NSCLC (excluding predominant squamous cell histology).

OSI3364g - A Phase III, multicenter, placebo-controlled, randomized clinical trial to evaluate the efficacy of Bevacizumab in combination with Erlotinib (Tarceva) compared with Erlotinib alone for the treatment of advanced NSCLC after failure of standard first-line chemotherapy.

PSOC 2003 - A Phase II study evaluating the efficacy of Gemcitabine, Carboplatin, Dexamethasone and Rituximab for previously treated lymphoid malignancies.

PSOC 2002 - Phase II study evaluating the efficacy of Rituximab and Dexamethasone in CD20+ , low grade and follicular NHL. Can treat patient more than once on this protocol.


PSOC 2301 - A Phase II Study of Bexxar Consolidation in Patients with B-Cell Chronic Lymphocytic Leukemia                 Following Fludarabine and Rituximab Chemotherapy.

CALGB 50303 - Phase III randomized study of R-CHOP v. dose-adjusted EPOCH-R with molecular profiling in untreated de novo diffuse Large B-cell lymphomas.

EPO-ANE 2007 - Phase II:  A Randomized, Open-Label, Comparative Study of Epoetin Alfa (Procrit) 80,000 Units or 120,000 Units Q3W Versus Darbepoetin Alfa (Aranesp) 500 mcg Q3W in Anemic Cancer Subjects Receiving Chemotherapy.

FHCRC
1926.00 - Phase I/II: Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine (Vidaza) givien in combination with Etanercept (Enbrel).